Drug Trial Radar · NCT07479576
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Nov 10, 2025
Primary completion
Apr 23, 2026
Study completion Apr 23, 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2106 versus Tremfye®(Guselkumab) in healthy subjects after a single dose.
Conditions
- Healthy Participants
Interventions
QL2106Drug
100mg/1 ml; single dose; subcutaneous injection
Tremfye®Drug
100mg/1 ml; single dose; subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics EndpointTime frame: 0-113 days
- Pharmacokinetics EndpointTime frame: 0-113 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.